Kadimastem Financial Statements From 2010 to 2025
| KMSTF Stock | USD 2.63 0.10 3.95% |
Check Kadimastem financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kadimastem's main balance sheet or income statement drivers, such as , as well as many indicators such as . Kadimastem financial statements analysis is a perfect complement when working with Kadimastem Valuation or Volatility modules.
Kadimastem |
Kadimastem Company Return On Asset Analysis
Kadimastem's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kadimastem Return On Asset | -0.75 |
Most of Kadimastem's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kadimastem is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Kadimastem has a Return On Asset of -0.7485. This is 91.45% lower than that of the Healthcare sector and 96.83% lower than that of the Biotechnology industry. The return on asset for all United States stocks is notably higher than that of the company.
Kadimastem Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kadimastem's current stock value. Our valuation model uses many indicators to compare Kadimastem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kadimastem competition to find correlations between indicators driving Kadimastem's intrinsic value. More Info.Kadimastem is rated fifth overall in return on equity category among its peers. It is rated second overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kadimastem's earnings, one of the primary drivers of an investment's value.About Kadimastem Financial Statements
Kadimastem stakeholders use historical fundamental indicators, such as Kadimastem's revenue or net income, to determine how well the company is positioned to perform in the future. Although Kadimastem investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kadimastem's assets and liabilities are reflected in the revenues and expenses on Kadimastem's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kadimastem. Please read more on our technical analysis and fundamental analysis pages.
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2008 and is based in Ness Ziona, Israel. Kadimastem operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Kadimastem Pink Sheet
Kadimastem financial ratios help investors to determine whether Kadimastem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kadimastem with respect to the benefits of owning Kadimastem security.